Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Larry Culp, Thomas Joyce, Alexandre Mérieux

Premium

Danaher said this week that President and CEO Lawrence Culp will retire in March 2015, and that he will be succeeded by current Executive VP Thomas Joyce.

After he steps down from his posts, Culp will continue serving Danaher in an advisory role into the first quarter of 2016. Culp has been Danaher's president and CEO for 13 years, the company said. Joyce has served Danaher as executive VP since 2006, and he currently is in charge of the company's diagnostics, life sciences, and water quality platforms. He has worked for the company in various capacities dating back to 1989.


BioMérieux said this week that Alexandre Mérieux has assumed the role of CEO. He was previously a deputy chief executive officer and corporate vice-president of microbiology unit and manufacturing and supply operations at the company.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.